Balancing Benefits and Risks of Spironolactone in HFpEF and Chronic Kidney Disease Patients: Mind the Gap of Biological Monitoring!

JACC: Heart Failure

Volumn 7, Issue 1, 2019, Pages 33-35

  Rossignol, Patrick ^a   Ferreira, João Pedro ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

Author keywords

chronic kidney disease; heart failure with preserved ejection fraction; hyperkalemia; spironolactone

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HORMONES AND AGENTS ACTING ON THE ENDOCRINE SYSTEM; PLACEBO; POTASSIUM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM INHIBITOR; SPIRONOLACTONE; UNCLASSIFIED DRUG; MINERALOCORTICOID ANTAGONIST;

ANAPHYLAXIS; CARDIORENAL SYNDROME; CHRONIC KIDNEY FAILURE; CLINICAL PROTOCOL; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EDITORIAL; ESTIMATED GLOMERULAR FILTRATION RATE; GYNECOMASTIA; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; KIDNEY DISEASE; MORBIDITY; MORTALITY; POTASSIUM BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SURVIVAL RATE; WORSENING RENAL FUNCTION; BIOLOGICAL MONITORING; HEART FAILURE; HEART STROKE VOLUME; RISK ASSESSMENT;

BIOLOGICAL MONITORING; HEART FAILURE; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; SPIRONOLACTONE; STROKE VOLUME;

EID: 85058693891     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2018.11.016     Document Type: Editorial

References (6)

1. Zannad, F., Rossignol, P., Cardiorenal syndrome revisited. Circulation 138 (2018), 929–944.
2. Beldhuis, I.E., Streng, K.W., Ter Maaten, J.M., et al. Renin-angiotensin system inhibition, worsening renal function, and outcome in heart failure patients with reduced and preserved ejection fraction: a meta-analysis of published study data. Circ Heart Fail, 10(2), 2017.
3. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 70 (2017), 776–803.
4. Pitt, B., Rossignol, P., Relation of serum potassium to cardiovascular events in patients with heart failure and preserved ejection fraction: “mind the gap.”. Am J Hypertens 31 (2018), 1087–1089.
5. Desai, A.S., Liu, J., Pfeffer, M.A., et al. Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial. J Card Fail 24 (2018), 313–320.
6. Beldhuis, I.E., Myhre, P.L., Claggett, B., et al. Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease. J Am Coll Cardiol HF 7 (2018), 25–32.